Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use

• US 10,669,347 B2
• Filed: 06/23/2017
• Issued: 06/02/2020
• Est. Priority Date: 06/08/2012
• Status: Active Grant

• Current Assignee: Sutro Biopharma, Inc.
• Original Assignee: Sutro Biopharma, Inc.
• Inventors: Thanos, Christopher D., McEvoy, Leslie, Yin, Gang, Penta, Kalyani, Baliga, Ramesh, Bajad, Sunil, Pollitt, Sonia, Murray, Chris, Steiner, Alex, Gill, Avinash
• Primary Examiner(s): Huynh, Phuong
• Application Number:
  US15/632,192
• Publication Number:
  US 20170362334A1
• Time in Patent Office: 1,075 Days
• CPC Class Codes: A61K 47/6817 Toxins
• CPC Class Codes: A61K 47/6855 the tumour determinant being from breast cancer cell
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2317/94 Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Claims

1. An isolated antibody of the IgG class comprising a heavy chain and a light chain, wherein:

the heavy chain comprises at least one non-natural amino acid residue at a specific site selected from the group consisting of heavy chain residue 52 according to the Kabat numbering scheme and heavy chain residues 119, 222, and 241 according to the EU index of Kabat;

or

the light chain comprises a non-natural amino acid residue at the light chain residue 152;

or a combination thereof;

or an aglycosylated variant thereof,

wherein each non-natural amino acid residue is independently selected from the group consisting of ortho-substituted tyrosine, meta substituted tyrosine, para-substituted phenylalanine, ortho-substituted phenylalanine, and meta-substituted phenylalanine.

2. The antibody of claim 1, wherein the antibody is a glycosylated.

3. The antibody of claim 2, wherein the light chain is selected from X, and K.

4. The antibody of claim 2, that is of a class or subclass selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

5. The antibody of claim 2,. wherein said non-natural amino acid residue comprises a moiety selected from the group consisting of amino, carboxy, acetyl, hydrazino, hydrazido, semicarbazido, sulfanyl, azido and alkynyl.

6. The antibody of claim 2, wherein each non-natural amino acid residue is according to the formula

7. The antibody of claim 2, wherein the non-natural amino acid residue is selected from the group consisting of p-acetyl-L-phenylalanine, O-methyl-L-tyrosine, 3-methyl-phenylalanine, O-4-allyl-L-tyrosine, 4-propyl-L-tyrosine, fluorinated phenylalanine, isopropyl-L-phenylalanine, p-azido-L-phenylalanine, p-acyl-L-phenylalanine, p-benzoyl-L-phenylalanine, p-iodo-phenylalanine, p-bromophenylalanine, p-amino-L-phenylalanine, isopropyl-L-phenylalanine, p-propargyloxy-phenylalanine, and p-azidomethyl-L-phenylalanine.

8. The antibody of claim 2, wherein the non-natural amino acid residue is p-azido-L-phenylalanine.

9. The antibody of claim 2, wherein the non-natural amino acid residue is p-azidomethyl-L-phenylalanine.

10. An antibody conjugate comprising the antibody of claim 2 linked to one or more therapeutic moieties or labeling moieties, wherein at least one therapeutic moiety or labeling moiety is linked to one of the non-natural amino acids, or a residue thereof.

11. The antibody conjugate of claim 10, wherein said antibody is linked to one or more drugs or polymers.

12. The antibody conjugate of claim 10, wherein said antibody is linked to one or more labeling moieties.

13. The antibody conjugate of claim 10, wherein said antibody is linked to one or more single chain binding domains (scFvs).

14. The antibody conjugate of claim 10, wherein said at least one therapeutic or labeling moiety is linked to the non-natural amino acid, or a residue thereof, via one or more linkers.

15. A composition comprising the antibody of claim 2, wherein said composition is substantially pure.

16. A composition comprising the antibody of claim 2, wherein said antibody is at least 95% by mass of the total antibody mass of said composition.